Opportunity Information: Apply for RFA AG 13 001
Apply for RFA AG 13 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Alzheimers Disease Cooperative Study (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Nov 28, 2011 and posted on Nov 28, 2011.
- Applicants must submit their applications by Mar 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $13,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Limited Competition Alzheimers Disease Cooperative Study (U19) funding opportunity, RFA-AG-13-001, is a National Institutes of Health (NIH) notice seeking a renewal application to continue the Alzheimers Disease Cooperative Study (ADCS) for another five-year cycle. The ADCS is positioned as a major, long-running clinical trials consortium focused on Alzheimer disease (AD), and the intent of this announcement is not to create a new network from scratch but to sustain and extend the existing ADCS infrastructure and mission. Because it is described as a limited competition, the applicant pool is constrained, reflecting that this is meant to renew an established program rather than open broad competition for new entrants.
At its core, the opportunity supports clinical research aimed at developing and testing interventions that could treat Alzheimer disease, slow its progression, delay onset, or prevent the disease. A key emphasis is placed on advancing interventions that may not be pursued by industry, which typically points to therapeutics, behavioral approaches, repurposed compounds, combination strategies, or other trial concepts that have scientific merit but limited commercial incentives. In practical terms, the grant is intended to maintain a coordinated consortium capable of designing and running multicenter clinical trials, standardizing procedures, managing data and regulatory requirements, and moving promising interventions through rigorous testing.
The award mechanism is a cooperative agreement (U19), meaning NIH expects substantial scientific or programmatic involvement during the project period rather than acting only as a passive funder. Under a cooperative agreement, the funded consortium generally collaborates closely with NIH staff on study priorities, trial conduct, milestones, and oversight, with an emphasis on shared responsibility for achieving the program goals. The activity category is Health, and the CFDA listing is 93.866 (Aging Research), aligning it with the National Institute on Aging mission space within NIH.
Financially, the opportunity lists an estimated total funding level of $13,000,000 for the program. The announcement also specifies that there is no cost sharing or matching requirement, so applicants are not required to provide non-federal matching funds as a condition of the award. The posting date and creation date are both November 28, 2011, with an original and current closing date of March 7, 2012, and an archive date of April 7, 2012, indicating the solicitation is historical and no longer open, but the details describe how the program was structured for that renewal cycle.
Eligibility includes a range of U.S.-based nonprofit and higher-education organizations. Eligible applicants include nonprofits with 501(c)(3) status (other than institutions of higher education), nonprofits without 501(c)(3) status (other than institutions of higher education), and both private and public/state-controlled institutions of higher education. Foreign institutions are explicitly not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. The announcement also disallows foreign components as defined by NIH Grants Policy, reinforcing that the funded consortium activities must be domestic in terms of applicant institution and allowable organizational components.
Administration of the opportunity is through NIH, and the full announcement is referenced via an NIH grants webpage link (http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-001.html). For access or technical issues, the contact provided is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV. Overall, this FOA is best understood as a renewal-focused, NIH-partnered cooperative agreement designed to preserve and strengthen a national clinical trials capability for Alzheimer disease, with special attention to interventions that might otherwise be neglected by commercial development pipelines.
Frequently Asked Questions (FAQs)
1. What is this funding opportunity?
This opportunity is the "Limited Competition Alzheimer's Disease Cooperative Study (U19)" funding opportunity announcement (FOA) RFA-AG-13-001 from the National Institutes of Health (NIH). It seeks a renewal application to continue the Alzheimer's Disease Cooperative Study (ADCS) for another five-year cycle.
2. What is the Alzheimer's Disease Cooperative Study (ADCS)?
The ADCS is described as a major, long-running clinical trials consortium focused on Alzheimer's disease (AD). It is positioned as an established national capability for designing and running multicenter clinical trials in Alzheimer's disease.
3. Is this FOA intended to create a brand-new clinical trials network?
No. The FOA states that the intent is not to create a new network from scratch. It is designed to sustain and extend the existing ADCS infrastructure and mission.
4. Why is the competition described as "limited"?
It is described as a limited competition because the applicant pool is constrained. The FOA is framed as a renewal of an established program rather than an open, broadly competed opportunity for new entrants.
5. What kind of research does this opportunity support?
The opportunity supports clinical research aimed at developing and testing interventions that could treat Alzheimer's disease, slow its progression, delay onset, or prevent the disease.
6. What types of interventions are especially emphasized?
A key emphasis is advancing interventions that may not be pursued by industry, including trial concepts with scientific merit but limited commercial incentives. The description points to examples such as therapeutics, behavioral approaches, repurposed compounds, and combination strategies.
7. What does the program fund in practical, operational terms?
The grant is intended to maintain a coordinated consortium capable of designing and running multicenter clinical trials, standardizing procedures, managing data and regulatory requirements, and moving promising interventions through rigorous testing.
8. What is the award mechanism for this opportunity?
The award mechanism is a cooperative agreement (U19).
9. What does a cooperative agreement (U19) mean for NIH involvement?
A cooperative agreement means NIH expects substantial scientific or programmatic involvement during the project period. The funded consortium is generally expected to collaborate closely with NIH staff on study priorities, trial conduct, milestones, and oversight, reflecting shared responsibility for achieving program goals.
10. What is the activity category and CFDA listing?
The activity category is Health, and the CFDA listing is 93.866 (Aging Research). This aligns the opportunity with the National Institute on Aging mission area within NIH.
11. How much total funding is associated with this FOA?
The opportunity lists an estimated total funding level of $13,000,000 for the program.
12. Is cost sharing or matching required?
No. The FOA specifies there is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of the award.
13. What are the key dates for this opportunity?
The posting date and creation date are both November 28, 2011. The original and current closing date is March 7, 2012. The archive date is April 7, 2012.
14. Is this funding opportunity currently open?
Based on the listed closing date (March 7, 2012) and archive date (April 7, 2012), this solicitation is historical and no longer open.
15. Who is eligible to apply?
Eligibility includes U.S.-based nonprofit and higher-education organizations, including: nonprofits with 501(c)(3) status (other than institutions of higher education), nonprofits without 501(c)(3) status (other than institutions of higher education), and private and public/state-controlled institutions of higher education.
16. Are foreign institutions eligible to apply?
No. Foreign institutions are explicitly not eligible to apply.
17. Are non-U.S. components of U.S. organizations eligible?
No. The FOA states that non-U.S. components of U.S. organizations are not eligible.
18. Are foreign components allowed under this FOA?
No. The announcement disallows foreign components as defined by NIH Grants Policy, reinforcing that the applicant institution and allowable organizational components must be domestic.
19. Which agency administers this opportunity?
This opportunity is administered through the National Institutes of Health (NIH).
20. Where can the full announcement be found?
The FOA is referenced via an NIH grants webpage: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-001.html
21. Who should be contacted for access or technical issues related to the FOA web posting?
The contact listed for access or technical issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
22. What is the main purpose of this renewal-focused FOA?
Its core purpose is to preserve, sustain, and strengthen a national Alzheimer's disease clinical trials capability by continuing the ADCS for another five-year cycle, with special attention to interventions that might otherwise be neglected by commercial development pipelines.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Small Grants Program for Cancer Epidemiology (R03)
Previous opportunity: Environmental Health Sciences (EHS) Core Centers (P30)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 13 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 13 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Centers in Primary Care Practice Based Research and Learning (P30) Apply for RFA HS 12 002 Funding Number: RFA HS 12 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Investigations on Primary Immunodeficiency Diseases (R01) Apply for PAR 12 036 Funding Number: PAR 12 036 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Small Grant Program For New Investigators (R03) Apply for PAR 12 045 Funding Number: PAR 12 045 Agency: National Institutes of Health Category: Health Funding Amount: $25,000 |
| Identifying Heart, Lung, and Blood Disease Causing Variants (R01) Apply for PAR 12 043 Funding Number: PAR 12 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Courses or Workshops in Metabolomics (R25) Apply for RFA RM 11 018 Funding Number: RFA RM 11 018 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Critical Congenital Heart Disease Newborn Screening Demonstration Program Apply for HRSA 12 127 Funding Number: HRSA 12 127 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Mentored Research Scientist Development Award in Metabolomics (K01) Apply for RFA RM 11 017 Funding Number: RFA RM 11 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Patient Centered Outcomes Research Institutional Award (K12) Apply for RFA HS 12 001 Funding Number: RFA HS 12 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $600,000 |
| New Methods for Understanding the Functional Role of Human DNA Sequence Variants in Complex Phenotypes (R01) Apply for RFA GM 13 002 Funding Number: RFA GM 13 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional Comprehensive Metabolomics Resource Cores (RCMRC) (U24) Apply for RFA RM 11 016 Funding Number: RFA RM 11 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Metabolomics Data Repository and Coordinating Center (DRCC) (U01) Apply for RFA RM 11 020 Funding Number: RFA RM 11 020 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Community Empowerment of People Against Tuberculosis (CEPAT) Apply for RFA 497 11 000005 Funding Number: RFA 497 11 000005 Agency: Indonesia USAID Jakarta Category: Health Funding Amount: $4,000,000 |
| Stroke Prevention/Intervention Research Program (SPIRP) (U54) Apply for RFA NS 12 007 Funding Number: RFA NS 12 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Radiological/Nuclear Medical Countermeasure Product Development Program (SBIRR43/R44) Apply for PA 12 044 Funding Number: PA 12 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ancillary Studies in Clinical Trials (R01) Apply for RFA HL 13 003 Funding Number: RFA HL 13 003 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Systems Strengthening for Better HIV/TB Patient Outcomes Apply for RFA 674 12 000002 Funding Number: RFA 674 12 000002 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $150,000,000 |
| Advanced Neural Prosthetics Research and Development (SBIR U44) Apply for PAR 12 054 Funding Number: PAR 12 054 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| National Public Health Practice and Resource Centers on Health Promotion for People with Disabilities Apply for CDC RFA DD12 1205 Funding Number: CDC RFA DD12 1205 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| National Training Mechanism (NTM) Apply for RFA 615 12 000001 Funding Number: RFA 615 12 000001 Agency: Kenya USAID Nairobi Category: Health Funding Amount: $40,000,000 |
| APHIAplus Northern Arid Lands (APHIAplus NAL) Apply for RFA 615 12 000002 Funding Number: RFA 615 12 000002 Agency: East Africa USAID Kenya Category: Health Funding Amount: $50,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 13 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.